Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company ...

Expanding demand for oligonucleotide therapeutics and GMP-grade reagents drives steady global market expansionAustin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Phosphoramidite Market Size & Growth Analysis ...

In a remarkable development that challenges our understanding of life’s origins, researchers have identified human-like DNA ...

Through a $650,000 USDA Grant Yi Li will study the unintended consequences of multiplex genome editing and how many ...

A research team drawn from Arc Institute, the University of California San Francisco, and the Fred Hutchinson Cancer Center, ...

Given the success of the Research Topic ‘Diversity and Molecular Diagnostics of Fungi and Oomycetes in Plants’ Volume I and the rapidly evolving subject ...

In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...